Antibody Discovery Services

VHH Antibody
Discovery

High-diversity, single-domain antibodies with unmatched precision and reliability in 4-5 months.

VHH antibodies are derived from camelids and are about half the size of scFv proteins, offering superior stability, solubility, and tissue penetration. Their simple structure enables efficient manufacturing and the ability to target hidden or complex epitopes with affinities down to the subnanomolar range.

Leveraging our exclusive alpaca breeding farm (300+ alpacas) and advanced phage display technology, Biointron completes 100+ projects annually, providing tailored solutions for therapeutic, diagnostic, and research applications.

Learn More

Single B Cell
Screening

Rapid antibody discovery with our proprietary AbDrop™ microfluidic platform in 2-3 months.

We directly screen up to 2 million plasma B cells in a single day, bypassing hybridoma limitations to capture naturally matured, antigen-specific antibodies. This high-throughput approach preserves natural heavy–light chain pairing, ensures exceptional specificity, and accelerates timelines from months to just weeks.

With comprehensive validation assays and proven expertise across challenging targets, Biointron provides a fast, reliable solution for antibody discovery.

Learn More

Hybridoma
Sequencing

Fast, accurate, full-length hybridoma sequencing in just 1 week.

Get reliable sequencing of the variable heavy (VH) and light (VL) domains from your hybridoma cells. This ensures long-term security against hybridoma instability, contamination, or loss, while enabling seamless recombinant antibody production, engineering, and IP protection.

Using 5’ RACE methodology and cross-verification across multiple clones, Biointron provides the foundation for downstream applications including scalable recombinant expression with just an additional 2 weeks and optimization services such as humanization and affinity maturation.

Learn More

HTP Fully
Human Antibody
Discovery

Safer and more efficient fully human antibodies in 2-3 months.

Biointron’s AbDrop™ microfluidics platform coupled with Cyagen’s HUGO-Ab™ fully human antibody mice, will directly generate fully human antibodies, without the need for humanization. This next-generation platform ensures enhanced accuracy, greater sequence diversity, and faster timelines at significantly lower cost.

All intellectual property rights for antibodies discovered belong to you. With millions of plasma B cells screened in a single day and natural heavy-light chain pairing preserved, Biointron provides a reliable path to high-quality, fully human antibodies ready for your research needs.

Learn More

Speak to an Expert

Featured Blog

High-Throughput Antibody Discovery with AbDrop™ & HUGO-Ab™: Faster, Fully Human Antibody Development

Discover fully human antibodies faster with AbDrop™ & HUGO-Ab™. Our high-throughput platform combines microfluidics and TurboKnockout® in just 3 months.

Aug 16, 2024

Exploring TCR-like Antibodies in Cancer Immunotherapy

Learn how TCR-like antibodies target intracellular tumor antigens through pMHC recognition. Explore their role, development, and potential in immunotherapy.

May 29, 2024

CAR-T Cell Engineering & Antibody Discovery: Advancing Targeted Cancer Therapy

Explore CAR-T cell therapy innovations, antibody discovery, and engineering advancements to improve targeting, safety, and treatment efficacy in cancer immunotherapy.

May 20, 2024